Zoll Acquires Revivant Corp.

In a transaction that gives the company a device for treating sudden cardiac arrest, Zoll Medical Corp. (Chelmsford, MA, USA) has acquired Revivant Corp. (Sunnyvale, CA, USA).

Zoll had earlier invested U.S.$7 million in Revivant stock and provided the company with $5 million of debt financing, for a 15% stake in the company and the option to acquire the remaining outstanding shares. Upon completion of the acquisition, Zoll will pay an additional $15 million and will also make clinical milestone payments, targeted at $15 million, tied to the completion of clinical trials of Revivant's device for treating sudden cardiac arrest, called AutoPulse. Revivant will become a subsidiary of Zoll, retaining its manufacturing functions in Sunnyvale. Zoll will consolidate marketing and sales operations at its headquarters in Chelmsford.

AutoPulse offers the potential of restoring near-normal blood flow levels in victims of sudden cardiac arrest (SCA) and is considered by many clinicians the single most important development in the treatment of SCA in the past 30 years. The device compresses the entire chest, moving much more blood than manual chest compressions. AutoPulse has been cleared by the U.S. Food and Drug Administration (FDA).

"We believe the AutoPulse will cause a sea change in how resuscitation is performed, and is the most important advance since the introduction of external defibrillation,” said Richard A. Packer, president and CEO of Zoll. "This acquisition presents an exciting opportunity to expand our presence in the resuscitation market and positions us as well for additional growth.”



Related Links:
Zoll
Revivant